ArticleBMC cancer2025

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system.

Ruichen Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.